We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
Swiss pharma firm Novartis has secured the European Commission (EC) approval for Mayzent (siponimod) to treat adult patients with secondary progressive multiple sclerosis (SPMS). The European regulator has
Clarivate Analytics has agreed to acquire US-based healthcare research and consulting company Decision Resources Group (DRG) from Piramal Enterprises for a purchase price of $950m. The UK-based analytics
The US Food and Drug Administration (FDA) has approved the Bridge Biotherapeutics’ Investigational New Drug (IND) application for BBT-176, used in the treatment of non-small cell lung cancer
Denmark-based pharmaceutical firm Novo Nordisk has secured the US Food and Drug Administration (FDA) approval of label expansion for Ozempic (semaglutide), based on its supplemental New Drug Application
Japanese pharmaceutical firm Astellas has unveiled plans to construct the Third Fermentation Building as a new manufacturing facility for active pharmaceutical ingredient (API) of Prograf (tacrolimus hydrate). The
ViiV Healthcare, a majority-owned company of GlaxoSmithKline (GSK), has received the Japan Ministry of Health, Labour and Welfare (MHLW) marketing approval of Dovato regimen for the treatment of
Janssen Pharmaceutical, a subsidiary of Johnson & Johnson, has submitted a Type II variation application to the European Medicines Agency (EMA) for the expanded indication of its SPRAVATO
Biogen has agreed to acquire Pfizer’s PF-05251749, intended for behavioural and neurological symptoms across various psychiatric and neurological diseases, for up to $710m. In addition, Biogen intends to
Novartis is set to partner with The National Health Service (NHS) England, a publicly funded national healthcare system in the UK, to address cardiovascular disease (CVD). According to
ViiV Healthcare, a joint venture between Pfizer and GlaxoSmithKline (GSK), has submitted a marketing authorisation application (MAA) to the European Medicines Agency (EMA) for its HIV drug Fostemsavir.